Epigallocatechin gallate (EGCG) inhibits lipopolysaccharide-induced inflammation in RAW 264.7 macrophage cells via modulating nuclear factor kappa-light-chain enhancer of activated B cells (NF- κ B) signaling pathway.
Level 5 - mechanism / opinion, no new human data
In vitro cell culture study (bench research without human data)
PubMed 37576060 · doi:10.1002/fsn3.3427
What was done
Researchers evaluated the anti-inflammatory effects of epigallocatechin-3-gallate (EGCG) in an in vitro model of lipopolysaccharide (LPS)-induced inflammation using murine RAW 264.7 macrophage cells. Measurements included cellular morphology, nitric oxide (NO) production, reactive oxygen species (ROS) levels, pro-inflammatory cytokines and enzymes (IL-1β, IL-6, TNF-α, iNOS) via RT-PCR/RNA-Seq, and NF-κB pathway activation (P-IκB/IκB and p-p65/p65 ratios) by Western blot.
What was found
EGCG normalized LPS-induced morphological deformation. Relative to LPS alone, EGCG reduced cellular NO to 32% and ROS to 45.4%. Inflammatory gene expression was markedly reduced: IL-1β (LPS 132.6 ± 14.6 vs EGCG 10.67 ± 3.65), IL-6 (LPS 2994.44 ± 178.5 vs EGCG 408.33 ± 52.34), TNF-α (LPS 27.11 ± 2.84 vs EGCG 1.22 ± 0.03), and iNOS (LPS 40.45 ± 11.17 vs EGCG 10.24 ± 0.89). Western blot showed EGCG diminished the P-IκB/IκB ratio by 75% and the p-p65/p65 ratio by 50% compared to LPS alone.
Why it matters
This study delineates specific molecular mechanisms by which EGCG attenuates LPS-driven inflammatory signaling and oxidative stress in macrophage cells.
Limits
This is strictly an in vitro study using a murine cell line (RAW 264.7) without animal or human validation. The abstract omits the EGCG concentrations tested and the number of experimental replicates.
Cited by
- supports EGCG (epigallocatechin gallate) is an effective inhibitor of LPS-induced inflammatory stimulation.